Muhondo yekurwisa cancer yepancreatic, mitsva uye mitsva yemakiriniki miedzo yave yakanyanya kuoma. Miedzo iyi inopa varwere mukana wekukurumidza kurapwa-okupedzisira izvo zvinogona kutungamira mukufambira mberi mukutsvagisa uye netarisiro yezvibodzwa zviri nani.
Kurapa kwese kuripo nhasi kwakatanga kutsvagirwa, kugadzirwa uye kubvumidzwa kuburikidza nekiriniki kuyedzwa - ongororo yetsvakiridzo inoongorora marapirwo matsva kana misanganiswa yemishonga iripo kuona kana ichibatsira kune vanhu vanorarama nepancreatic cancer. Pancreatic cancer iri kuramba ichinyanya kunetsa pasirese, ichigara ichifambisa kudiwa kwehunyanzvi hwekurapa uye kuedza kwekuvandudza zvinodhaka. Zvido zvisina kuzadziswa zvine chekuita nechirwere ichi zviri kukwezva makambani mazhinji epasi rose kuti aise mari muindasitiri iyi. Izvi zvinhu zvakasanganiswa nekukwira kwemari yehutano pasi rese zvichawedzera kukura kwemusika. Chirevo chakabva kuGlobal Market Insight chakataura kuti Pancreatic Cancer Treatment Market saizi inotarisirwa kuunza mari yakawanda kubva muna 2021 kusvika 2027. Mushumo wacho wakaenderera mberi uchiti: “Gomarara repancreatic rinoonekwa seimwe yemhando dzegomarara rinotanga mupancreatic tishu uye rinogona kukurumidza. kupararira kunhengo dziri pedyo. Sarudzo dzemararamiro asina kunaka akadai sekuputa, kunwa doro uye kunwa fodya pamwe nemararamiro ane chekuita nezvirwere zvakaita sekufuta uye chirwere cheshuga ndezvimwe zvezvikonzero zvakakosha zvegomarara repancreatic. The American Cancer Society inofungidzira kuti vanhu vanopfuura 60,000 2021 vokuAmerica vachabatwa gomarara repancreatic muna XNUMX. Maitiro akafanana ari kupupurirwa mune dzimwe nzvimbo dzakawanda dzepasi izvo zvichanyatsotsigira mafambiro eindasitiri.” Anoshanda biotech uye makambani emishonga mumisika svondo rino anosanganisira Oncolytics Biotech® Inc., Bristol Myers Squibb, Seagen Inc., Exact Sciences Corp., Kura Oncology, Inc.
Global Market Insight yakawedzera kuti: "Chemotherapy, immunotherapy, yakanangwa kurapa, uye mahormone therapy, pakati pevamwe, ndiwo marudzi akasiyana epancreatic cancer kurapwa sarudzo. Pakati peizvi, chikamu chekurapa chakanangwa chinogona kutora chikamu chakanaka chemusika panosvika 2027. Targeted therapy inonangana nemapuroteni egomarara, majini, kana matishu anobatsira mukukura kwegomarara. Kurapwa kwacho kunovharisa kukura uye kupararira kwemasero egomarara uku uchidzikamisa kukuvara kune iwo ane hutano. Kurapa kwakanangwa kuchaona kuwedzera kudiwa kwekurapwa kwegomarara repancreatic mumakore anotevera. "
Oncolytics Biotech® Inopa Yakanaka Kuchengetedzeka Kuwedzeredza paPancreatic Cancer Cohort yayo yeMulti-Indication Phase 1/2 Gastrointestinal Cancer Kuedzwa - Oncolytics Biotech®) nhasi yazivisa kupedzwa kwakabudirira kwekumhanya kwevarwere-vatatu kuchengetedza-mukati kwepancreatic cancer cohort ye. chikamu 1/2 GOBLET chidzidzo chinotevera kuongororwa neData Safety Monitoring Board (DSMB) yechidzidzo. DSMB haina kuona nezvekuchengetedza mune varwere ava uye yakakurudzira kuti chidzidzo chienderere mberi sezvakarongwa. Iyo yekuchengetedza-muyedzo yechitatu-mutsara metastatic colorectal cancer cohort inoramba ichienderera.
Chidzidzo cheGOBLET chiri kutungamirwa neAIO, boka rinotungamira remubatanidzwa wekurapa oncology boka rakavakirwa kuGermany, uye rakagadzirirwa kuongorora kuchengetedzeka uye kushanda kwepelareorep musanganiswa neRoche's anti-PD-L1 checkpoint inhibitor atezolizumab muvarwere vane metastatic pancreatic, metastatic. colorectal, uye advanced anal cancers. Chidzidzo ichi chinoramba chichienderera mberi uye chinotarisirwa kunyoresa varwere kunzvimbo gumi nemana dzekuyedza makiriniki muGermany.
Iyo GOBLET yekudzidza's pancreatic cancer cohort inowedzera yakambotaurwa dhata rekiriniki rinoratidza synergy uye anti-gomarara chiitiko chepelareorep chakasanganiswa necheki inhibition mupancreatic cancer varwere vakafambira mberi mushure mekutanga kurapwa (link kune PR, chinongedzo kune poster). Iyo zvakare inovaka pane yekutanga data yekiriniki yakaratidza kuwedzera kukuru kupfuura 80% yepakati kufambira mberi-kusina kupona mupancreatic cancer varwere vane yakaderera mazinga eECACAM6 kutaura vakagamuchira pelareorep pamwe chete nechemotherapy (link kune PR, chinongedzo kune poster). Pamusoro pekuongorora kuchengetedzwa uye kushanda kwepelareorep-atezolizumab kurapwa, GOBLET inodawo kuratidza kugona kweCEACAM6 uye T cell clonality sekufungidzira biomarkers, izvo zvinogona kuwedzera mukana wekubudirira kwezvidzidzo zvekunyoresa zveramangwana nekubvumira kusarudzwa kwevarwere vakakodzera. .
Seagen Inc. nguva pfupi yadarika yakazivisa data kubva kuchikamu chekutanga chekuyedza kiriniki ichibatanidza SEA-CD1 nechemotherapy uye anti-PD-40 muvarwere vane metastatic PDAC pamusangano wepagore weASCO GI uri kuitika muSan Francisco, Ndira 1 - 20, 22. SEA. -CD2022 ibhuku, kuongorora, nonfucosylated monoclonal receptor-agonistic antibody inotungamirirwa kuCD40, iyo inoratidzirwa pamasero e-antigen-presenting. Mune preclinical modhi, musanganiswa weSEA-CD40 uye chemotherapy yakakonzera antitumor chiitiko icho chinowedzerwa nekuwedzerwa ne-anti-PD-40 kurapwa.
Muchikamu chekutanga chekuedza, SEA-CD1 yakabatanidzwa nechemotherapy [gemcitabine uye nab-paclitaxel (GnP)], uye anti-PD-40 (pembrolizumab), muvarwere ve1 vane metastatic PDAC isina kurapwa. Pakati peizvi, varwere ve61 vakagamuchira 40 mcg / kg uye varwere ve10 vakagamuchira 21 mcg / kg yeSEA-CD30. Mhedziso dzakakosha dzinosanganisira yakasimbiswa chinangwa chekupindura mwero (cORR) paRECIST v40 nemuongorori, kufambira mberi-kusina kupona (PFS) uye kupona kwese (OS) "Bato rekutanga rinokurudzira zvichienderana nezvakaitika kare chemotherapy. Kuenderera mberi kwekupona kunodiwa kuzivisa matanho edu anotevera mugomarara repancreatic, "akadaro Roger Dansey, MD, Chief Medical Officer kuSeagen. "Tiri kuenderera mberi nekuenderera mberi kwechikamu chechipiri chekuedza kweSEA-CD1.1 mu melanoma uye mune isiri-diki kenza yemapapu."
Exact Sciences Corp. ichangobva kuzivisa data yekushanda kwechizvarwa chechipiri cheCologuard (multi-target stool DNA) bvunzo inoratidza kunzwisiswa kwese kwe95.2% yegomarara remukati (CRC) pane chaiyo ye92.4% yemasampuri asina kunaka akasimbiswa necolonoscopy. Ongororo yeboka diki yakaratidza 83.3% senitivity ye-high-giredhi dysplasia, maronda ane ngozi zvakanyanya, uye 57.2% kune ese epamberi precancerous maronda. Iyi data ichaunzwa Ndira 22 kuASCO GI mune poster yakanzi, "Yechipiri-chizvarwa Multi-target Stool DNA Panel Inonyatsoona Colorectal Cancer uye Yepamberi Precancerous Maronda."
Cologuard ndiyo yekutanga uye yega FDA-yakatenderwa, isiri-invasive stool DNA bvunzo inoshandiswa kuongorora avhareji-njodzi yeCRC. Exact Sciences iri kugadzira chizvarwa chechipiri Cologuard kuti ivandudze hunhu uye precancer sensitivity yebvunzo, kuderedza mwero wekunyepa uye kuwedzera chiyero chekuonekwa kwemaronda ekare. Chidzidzo ichi chinoratidza kugona kwepaneru ine rusarura rwakanyanya rwemethylated DNA mamaki uye fecal hemoglobin kuti iite zviri zviviri mumamiriro epasirese. Kana ikabvumidzwa, chizvarwa chechipiri cheCologuard bvunzo inogona kubatsira kuwedzera huwandu hwekuongorora ichitumira vanhu vashoma kuti vatevere colonoscopies zvisina basa uye nekuona mamwe maprecancer epamberi vasati vaenda kugomarara, zvichibatsira kudzivirira chirwere.
Bristol Myers Squibb nguva pfupi yadarika akazivisa Komiti yeMishonga Yekushandisa Kwevanhu (CHMP) yeEuropean Medicines Agency (EMA) yakakurudzira kubvumidzwa kweBreyanzi (lisocabtagene maraleucel; liso-cel), CD19-inotungamirwa chimeric antigen receptor (CAR) T cell. kurapwa kwekurapa kwevarwere vakura vane kudzoka kana kuramba (R/R) kuparadzira hombe B-cell lymphoma (DLBCL), primary mediastinal hombe B-cell lymphoma (PMBCL), uye follicular lymphoma giredhi 3B (FL3B) mushure memitsara miviri kana kupfuura. ye systemic therapy. Kurudziro yeCHMP yave kuzoongororwa neEuropean Commission (EC), iyo ine mvumo yekubvumidza mishonga yeEuropean Union (EU).
Kura Oncology, Inc., kambani yekiriniki-nhanho biopharmaceutical yakazvipira kuzadzikisa vimbiso yemishonga chaiyo yekurapa gomarara, nguva pfupi yadarika yakazivisa kuti US Food and Drug Administration (FDA) yasimudza chikamu chekiriniki yekubata paKOMET-001 Phase. 1b yekudzidza yeKO-539 kune varwere vane kudzokazve kana kuti refractory acute myeloid leukemia (AML). Kubatwa nechipatara zvishoma kwakasimudzwa zvichitevera chibvumirano neFDA pamusoro peKambani yekuderedza danho rekupatsanurwa kwechirwere, chiitiko chakashata chinozivikanwa chine chekuita nekusiyanisa vamiririri mukurapwa kweAML.
